Page 108 - Read Online

Rosenwasser RH, Owens GK, Koch WJ, Greig NH, Dumont AS. 56. Wetsel RA. Structure, function and cellular expression of complement
TNF‑α induces phenotypic modulation in cerebral vascular smooth anaphylatoxin receptors. Curr Opin Immunol 1995;7:48‑53.
muscle cells: implications for cerebral aneurysm pathology. J Cereb 57. Dunkelberger JR, Song WC. Complement and its role in innate and
Blood Flow Metab 2013;33:1564‑73. adaptive immune responses. Cell Res 2010;20:34‑50.
36. Aoki T, Kataoka H, Morimoto M, Nozaki K, Hashimoto N. 58. Ducruet AF, Zacharia BE, Hickman ZL, Grobelny BT, Yeh ML,
Macrophage‑derived matrix metalloproteinase‑2 and ‑9 Sosunov SA, Connolly ES Jr. The complement cascade as a
promote the progression of cerebral aneurysms in rats. Stroke therapeutic target in intracerebral hemorrhage. Exp Neurol
2007;38:162‑9. 2009;219:398‑403.
37. Aoki T, Kataoka H, Shimamura M, Nakagami H, Wakayama K, 59. Gasque P, Singhrao SK, Neal JW, Wang P, Sayah S, Fontaine M,
Moriwaki T, Ishibashi R, Nozaki K, Morishita R, Hashimoto N. Morgan BP. The receptor for complement anaphylatoxin C3a is
NF‑kappaB is a key mediator of cerebral aneurysm formation. expressed by myeloid cells and nonmyeloid cells in inflamed human
Circulation 2007;116:2830‑40. central nervous system: analysis in multiple sclerosis and bacterial
38. Ishibashi R, Aoki T, Nishimura M, Hashimoto N, Miyamoto S. meningitis. J Immunol 1998;160:3543‑54.
Contribution of mast cells to cerebral aneurysm formation. Curr 60. Mack WJ, Ducruet AF, Hickman ZL, Garrett MC, Albert EJ,
Neurovasc Res 2010;7:113‑24. Kellner CP, Mocco J, Connolly ES Jr. Early plasma complement
39. Pera J, Korostynski M, Krzyszkowski T, Czopek J, Slowik A, C3a levels correlate with functional outcome after aneurysmal
Dziedzic T, Piechota M, Stachura K, Moskala M, Przewlocki R, subarachnoid hemorrhage. Neurosurgery 2007;61:255‑60.
Szczudlik A. Gene expression profiles in human ruptured and 61. Lloyd‑Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB,
unruptured intracranial aneurysms: what is the role of inflammation? Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N,
Stroke 2010;41:224‑31. Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D,
40. Kadirvel R, Ding YH, Dai D, Zakaria H, Robertson AM, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D,
Danielson MA, Lewis DA, Cloft HJ, Kallmes DF. The influence of Nichol G, O’Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P,
hemodynamic forces on biomarkers in the walls of elastase‑induced Stafford R, Steinberger J, Thom T, Wasserthiel‑Smoller S, Wong N,
aneurysms in rabbits. Neuroradiology 2007;49:1041‑53. Wylie‑Rosett J, Hong Y; American Heart Association Statistics
41. Metz RP, Patterson JL, Wilson E. Vascular smooth muscle cells: Committee and Stroke Statistics Subcommittee. Heart disease
isolation, culture, and characterization. Methods Mol Biol and stroke statistics‑‑2009 update: a report from the American
2012;843:169‑76. Heart Association Statistics Committee and Stroke Statistics
42. Aoki T, Kataoka H, Moriwaki T, Nozaki K, Hashimoto N. Role of Subcommittee. Circulation 2009;119:480‑6.
TIMP‑1 and TIMP‑2 in the progression of cerebral aneurysms. Stroke 62. Walport MJ. Complement. Second of two parts. N Engl J Med
2007;38:2337‑45. 2001;344:1140‑4.
43. Aoki T, Fukuda M, Nishimura M, Nozaki K, Narumiya S. Critical role 63. Ricklin D, Lambris JD. Complement‑targeted therapeutics. Nat
of TNF‑alpha‑TNFR1 signaling in intracranial aneurysm formation. Biotechnol 2007;25:1265‑75.
Acta Neuropathol Commun 2014;2:34. 64. Qu H, Ricklin D, Lambris JD. Recent developments in low molecular
44. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): weight complement inhibitors. Mol Immunol 2009;47:185‑95.
an ancient family with structural and functional diversity. Biochim 65. Zanier ER, Zangari R, Munthe‑Fog L, Hein E, Zoerle T, Conte V,
Biophys Acta 2010;1803:55‑71. Orsini F, Tettamanti M, Stocchetti N, Garred P, De Simoni MG.
45. Aoki T, Kataoka H, Ishibashi R, Nozaki K, Hashimoto N. Cathepsin B, Ficolin‑3‑mediated lectin complement pathway activation in patients
K, and S are expressed in cerebral aneurysms and promote the with subarachnoid hemorrhage. Neurology 2014;82:126‑34.
progression of cerebral aneurysms. Stroke 2008;39:2603‑10. 66. Ostergaard JR, Kristensen BO, Svehag SE, Teisner B, Miletic T.
46. Nordon IM, Hinchliffe RJ, Holt PJ, Loftus IM, Thompson MM. Immune complexes and complement activation following rupture
Review of current theories for abdominal aortic aneurysm of intracranial saccular aneurysms. J Neurosurg 1987;66:891‑7.
pathogenesis. Vascular 2009;17:253‑63. 67. Lindsberg PJ, Ohman J, Lehto T, Karjalainen‑Lindsberg ML,
47. Capella JF, Paik DC, Yin NX, Gervasoni JE, Tilson MD. Complement Paetau A, Wuorimaa T, Carpén O, Kaste M, Meri S. Complement
activation and subclassification of tissue immunoglobulin G in the activation in the central nervous system following blood‑brain barrier
abdominal aortic aneurysm. J Surg Res 1996;65:31‑3. damage in man. Ann Neurol 1996;40:587‑96.
48. Chyatte D, Bruno G, Desai S, Todor DR. Inflammation and 68. Rosti V. The molecular basis of paroxysmal nocturnal hemoglobinuria.
intracranial aneurysms. Neurosurgery 1999;45:1137‑46. Haematologica 2000;85:82‑7.
49. Reich NC. Janeway’s immunobiology. Q Rev Biol 2008;83:403. 69. Davis AE 3rd, Mejia P, Lu F. Biological activities of C1 inhibitor. Mol
50. Cebral JR, Castro MA, Burgess JE, Pergolizzi RS, Sheridan MJ, Immunol 2008;45:4057‑63.
Putman CM. Characterization of cerebral aneurysms for 70. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B,
assessing risk of rupture by using patient‑specific computational Aygoeren‑Pürsün E, Craig T, Binkley K, Hebert J, Ritchie B, Bouillet L,
hemodynamics models. AJNR Am J Neuroradiol 2005;26:2550‑9. Betschel S, Cogar D, Dean J, Devaraj R, Hamed A, Kamra P, Keith PK,
51. Cebral JR, Mut F, Weir J, Putman C. Quantitative characterization Lacuesta G, Leith E, Lyons H, Mace S, Mako B, Neurath D, Poon MC,
of the hemodynamic environment in ruptured and unruptured brain Rivard GE, Schellenberg R, Rowan D, Rowe A, Stark D, Sur S, Tsai E,
aneurysms. AJNR Am J Neuroradiol 2011;32:145‑51. Warrington R, Waserman S, Ameratunga R, Bernstein J, Björkander J,
52. Rinkel GJ, Djibuti M, Algra A, van Gijn J. Prevalence and risk Brosz K, Brosz J, Bygum A, Caballero T, Frank M, Fust G, Harmat G,
of rupture of intracranial aneurysms: a systematic review. Stroke Kanani A, Kreuz W, Levi M, Li H, Martinez‑Saguer I, Moldovan D,
1998;29:251‑6. Nagy I, Nielsen EW, Nordenfelt P, Reshef A, Rusicke E, Smith‑Foltz S,
53. Starke RM, Chalouhi N, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Späth P, Varga L, Xiang ZY. 2010 International consensus algorithm for
Rosenwasser RH, Wada K, Shimada K, Hasan DM, Greig NH, the diagnosis, therapy and management of hereditary angioedema.
Owens GK, Dumont AS. Critical role of TNF‑α in cerebral aneurysm Allergy Asthma Clin Immunol 2010;6:24.
formation and progression to rupture. J Neuroinflammation 71. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P,
2014;11:77. Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM,
54. Bacle F, Haeffner‑Cavaillon N, Laude M, Couturier C, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA,
Kazatchkine MD. Induction of IL‑1 release through stimulation of Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor
the C3b/C4b complement receptor type one (CR1, CD35) on human eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med
monocytes. J Immunol 1990;144:147‑52. 2006;355:1233‑43.
55. Haas PJ, van Strijp J. Anaphylatoxins: their role in bacterial infection 72. Yang J, Ahn HN, Chang M, Narasimhan P, Chan PH, Song YS.
and inflammation. Immunol Res 2007;37:161‑75. Complement component 3 inhibition by an antioxidant is

100 Neuroimmunol Neuroinflammation | Volume 2 | Issue 2 | April 15, 2015